EGFR and non-small cell lung carcinoma: Among the available therapeutic options, platinum-based chemotherapies (cisplatin and paclitaxel) are the standard of care for advanced NSCLC, while TKIs against the EGFR, gefitinib and erlotinib, are the first-line treatment for patients with EGFR mutation.